Carmot Therapeutics Email Format
Research Services2-10 Employees
Carmot Therapeutics is a small company in the Research Services industry with 2 to 10 employees. It develops drug candidates and has advanced a daily GLP-1/GIP dual receptor modulator, CT-868, into Phase II trials for overweight or obesity and related diabetes indications. The company publicly entered the capital markets in 2023 through an initial public offering. Press coverage notes financing activity related to Carmot and its obesity-focused programs, reflecting engagement with the broader weight-loss and diabetes treatment landscape. Carmot maintains an online presence at carmot.us and provides information about the company on professional networks.